Interventions that can block the transmission of malaria-causing Plasmodium falciparum (Pf) between the human host and Anopheles vector have the potential to reduce the incidence of malaria. Pfs48/45 is a gametocyte surface protein critical for parasite development and transmission, and its targeting by monoclonal antibody (mAb) 85RF45.1 leads to the potent reduction of parasite transmission. Here, we reveal how the Pfs48/45 6C domain adopts a (SAG1)-related-sequence (SRS) fold. We structurally delineate potent epitope I and show how mAb 85RF45.1 recognizes an electronegative surface with nanomolar affinity. Analysis of Pfs48/45 sequences reveals that polymorphisms are rare for residues involved at the binding interface. Humanization of rat-derived mAb 85RF45.1 conserved the mode of recognition and activity of the parental antibody, while also improving its thermostability. Our work has implications for the development of transmission-blocking interventions, both through improving vaccine designs and the testing of passive delivery of mAbs in humans.
M alaria is a global health priority, with an estimated 216 million cases worldwide in 2016 alone 1 . The Plasmodium falciparum (Pf) parasite is responsible for most malaria-related mortalities, with over two-thirds occurring in children under 5 years of age. Disrupting the Pf life cycle as the parasite circulates between humans and Anopheles mosquitoes has the potential to reduce infections within communities, and thus reduce illness and death 2 . It was recognized decades ago that antibodies have the potential to inhibit onward transmission of the parasite when passed by malaria-infected humans to the Anopheles mosquito vector [3] [4] [5] . Transmission-blocking vaccines (TBVs) are based on this principle, and aim to elicit antibodies in humans that can reduce Pf transmission to the vector when mosquitoes ingest these antibodies during feeding 6 . Target proteins for TBV development are located on the surface of gametocytes/gametes (P48/45 7 , P230 8 ) and zygotes/ookinetes (P25, P28) 9, 10 , or are expressed within the mosquito midgut (e.g. APN1 11 and FREP1 12 ).
Pfs48/45 is a cysteine-rich surface protein that plays a critical role in male gamete fertility 13 . Antibodies against Pfs48/45 have been shown to prevent parasite development and transmission 14, 15 . Because Pfs48/45 is located on gametocytes/ gametes that circulate in humans, naturally occurring antibodies against Pfs48/45 can be elicited in individuals living in malariaendemic areas, and these antibodies have been demonstrated to possess transmission-blocking activity [16] [17] [18] [19] [20] [21] .
Pfs48/45 is organized into three domains, and epitope mapping has identified at least five predominant sites of antibody recognition that span its primary sequence 22, 23 (Fig. 1a) . Human, murine, and rat monoclonal antibodies (mAbs) have been derived that target epitopes I, IIb, III, and V 5, [24] [25] [26] . Of these, mAb 85RF45.1, derived from rats immunized with whole gametocytes followed by fusion and screening by enzyme-linked immunosorbent assay for Pfs48/45 antibodies, was shown to be the most potent at inhibiting parasite transmission to Anopheles mosquitoes 24 . mAb 85RF45.1 is a rat IgG1 that binds to epitope I on Pfs48/45 24 .
A three-dimensional structure of Pfs48/45 remains elusive. Such information would provide useful in devising strategies for improved recombinant expression of immunogens; indeed, monodisperse Pfs48/45 has been challenging to obtain and development of homogeneous and stable recombinant constructs is an area of intense research 7, 25, [27] [28] [29] [30] . A molecular understanding of mAb 85RF45.1 binding to Pfs48/45 would also provide the blueprints for the development of next-generation Pfs48/45 immunogens that optimally present this potent epitope to be tested as TBVs. In addition, molecular details of this antibody-antigen interaction could facilitate the development of new antibody interventions. Here, we present the threedimensional structure of the Pfs48/45 6C domain and delineate the potent 85RF45.1 epitope structurally. We also provide molecular details for the development of mAb TB31F, a humanized version of rat mAb 85RF45.1 with improved biophysical properties, now undergoing preclinical development.
Results mAb 85RF45.1 recognizes a conformational epitope on Pfs48/ 45. To uncover the potent epitope on Pfs48/45 bound by transmission-blocking mAb 85RF45.1, we solved the co-crystal structure of the 85RF45.1 Fab-Pfs48/45 6C complex to 2.7 Å resolution ( Fig. 1b and Supplementary Table 1 ). All six complementarity determining regions (CDRs) are involved in mediating interactions with a conformational epitope on Pfs48/45 (Fig. 1c) . The buried surface area of mAb 85RF45.1 on its antigen is extensive (1039 Å 2 ), and primarily contributed by the heavy chain (650 Å 2 ), and less by the light chain (389 Å 2 ) (Supplementary Table 2 ). Ten discontinuous residues on Pfs48/45 are contacted by the antibody to form salt bridges or H-bonds,  namely G346, D347, D351, Q355, E365, K394, K413, K414, D415,  and K416 (Fig. 1c, insets) . Our structural delineation of the antibody-antigen complex corroborates the importance of disulfide bonds and protein conformation for epitope I established by previous biochemical characterization 24 .
The Pfs48/45 6C domain adopts a SRS fold. Analysis of the Pfs48/45 6C sequence reveals that proteins with the highest sequence identity include Pfs48/45 orthologs from Plasmodium vivax, malariae, and ovale (62-64%), as well as the gamete surface protein Pfs47 (27%) (Fig. 2a) . Our crystal structure of Pfs48/45 6C now also allows for a complete analysis of its homology. Pfs48/45 6C contains a mix of parallel and anti-parallel ß-strands that organize in a five-on-four ß sandwich (a, a′, c, e, and f on b, d, g, and h), which is consistent with the (SAG1)-relatedsequence (SRS) fold. The six cysteines in Pfs48/45 6C are paired in a C1-C2, C3-C6, C4-C5 disposition: C298-C327, C344-C412, and C352-C410 (Figs. 1a and 2b), as consistent with previous biochemical analysis of tryptic peptides by LC-MS/MS 30 . These disulfide bonds connect strands a and b, strands c and g, and loop d-d′ to strand g, respectively (Fig. 2b) . The three proteins of known structure with highest structural similarity with Pfs48/45 6C are schizont surface protein Pf12 (Z-score 12.9), merozoite surface protein Pf41 (Z-score 12.0), and Toxoplasma gondii sporozoite-specific SAG protein (Z-score 10.5) (Fig. 2c) 31 . Pfs48/ 45 6C only shares 16-22% sequence identify with these proteins and consequently displays unique surface properties likely involved in male gamete fertility and giving the protein its distinct immunogenicity (Supplementary Figure 1) . N-linked glycosylation improves expression of Pfs48/45 6C. The Pfs48/45 6C construct used for structure determination was expressed in HEK293 mammalian cells, thus in a system capable of post-translational modifications. The primary amino acid sequence of Pfs48/45 6C encodes for two putative N-linked glycosylation sites when expressed in mammalian cells: N299 (NFS) and N303 (NVS), both located near the N terminus of the construct. Our crystal structure revealed that N303 is indeed glycosylated, and harbors a NAG residue residual from Endoglycosidase H (Endo H) treatment (Fig. 3a) . In fact, NAG303 forms H-bonds with D390 and D391 of the neighboring loop and buries approximately 150 Å 2 of surface area on the two loops that connect strands a-a′ and strands e-f (Fig. 3a) . On the other hand, N299, which immediately follows C298, is not glycosylated, and instead its sidechain plays an important structural role in the strand a-loop-strand a′ motif, mediating H-bonds with S301 (Fig. 3a) . To determine whether N-linked glycosylation played a role in the expression of Pfs48/ 45 6C in our HEK293 system, we created single and double mutants removing the N-linked glycosylation sequon by introducing S301A and S305A mutations. Expression tests showed a substantial decrease in recovered protein levels when removing N303 glycosylation, with the double mutant yielding almost no Pfs48/45 6C (Fig. 3b) . N-linked glycosylation was also critical to obtain a monomeric and monodisperse Pfs48/45 6C sample, as observed by size-exclusion chromatography (Fig. 3c) . Importantly, the N303 N-linked glycan is distally located from the 85RF45.1 epitope. N-linked glycosylation resulting from expression in mammalian cells therefore favors production of well-folded Pfs48/45 6C, without affecting exposure of potent epitope I.
The 85RF45.1 epitope contains few sequence polymorphisms. Next, we structurally mapped the sequence diversity documented for Pfs48/45. Deposited sequences of the Pfs48/45 6C domain from UniProt (28), NCBI (61), and PlasmoDB (195) revealed the following polymorphisms: V/D304, S/G313, L/I314, D/G315, S/ N/C322, E/G333, I/V349, Q/L355, V/A356, A/T387, K/R404, K/ E414, and T/I422 (Fig. 4a) . The five Pfs48/45 residues predominantly involved in interacting with 85RF45.1 (D347, D351, K413, D415, and K416; all mediating extensive H-bonds/salt bridges and with individual BSA > 75 Å 2 ) are invariant (Fig. 4a) . Two other Pfs48/45 residues mediating H-bonds with 85RF45.1 (E365 and K394) are also invariant (Fig. 4a) 32 . 85RF45.1 buries 36, 46 , and 20 Å 2 of surface area on these three residues, respectively. Binding measurements of 85RF45.1 Fab to Pfs48/45 6C constructs possessing single point mutations that represent these polymorphisms revealed that the antibody is still capable of binding its epitope with nanomolar affinity (Fig. 4c) . We conclude that the 85RF45.1 epitope is predominantly conserved, with rare polymorphisms located in secondary epitope regions (individual residues each represent <5% of total buried surface area).
Humanization of mAb 85RF45.1. Next, we sought to humanize mAb 85RF45.1, introducing as much human sequence as possible while retaining sequences that preserve the binding characteristics of the antibody. The closest human V germlines to the parental rat sequence were found to be IGLV6-57 (66.2% for the light chain) and IGHV3-7 (84.0% for the heavy chain). Three humanized light chains and three humanized heavy chains were designed, all exceeding our threshold humanness scores (Supplementary Figure 2 ). In all cases, CDRs remained unchanged. Three humanized light and heavy chains were combined to create a total of nine fully-humanized variant antibodies (Supplementary Figure 2 ). All three light chain combinations within the HC2 group bound the antigen similarly and the HC2 group affinities were higher than the HC1 and HC3 groups (Supplementary Figure 2) . The HC2-LC1 (hereafter named TB31F, Fig. 5a ) was selected for further characterization based on high binding activity and high human-like scores.
To characterize the ability of mAb TB31F to recognize Pfs48/ 45, we solved the crystal structure of TB31F Fab in complex with Pfs48/45 6C to 2.6 Å resolution ( Fig. 5b and Supplementary Table 1 ). As expected from the preservation of CDR residues during humanization, mAb TB31F forms similar contacts with Pfs48/45 6C as mAb 85RF45.1 (Fig. 5b and Supplementary  Table 2) , with slight differences primarily attributable to flexible loops in Pfs48/45 6C and crystal packing contacts. Next, we investigated whether amino acid changes in the antibody framework regions during humanization impacted the structural disposition of CDRs. Crystal structures of unliganded 85RF45.1 Fab and unliganded TB31F Fab, solved to 3.15 and 1.5 Å resolutions, respectively, revealed a strikingly similar paratope configuration (Fig. 5c ). The all-atom rmsd between the two unliganded variable domains is 0.88 Å, primarily arising from differences in loop conformations within the framework regions (Fig. 5c ). These structures also revealed how the variable region is optimally configured for binding Pfs48/45 even when unliganded (all-atom rmsd 85RF45.1 bound/unbound : 1.52 Å; TB31F bound/unbound : 1.25 Å). Despite this high structural similarity, amino acid changes during humanization resulted in electrostatic surfaces that are considerably different between the 85RF45.1 and TB31F variable regions, indicating the attainment of antibody resurfacing (Fig. 5d) . Importantly, both 85RF45.1 Fab and TB31F Fab bound the antigen with nanomolar binding affinities ( Figures 5 and 6 ). These desirable biophysical properties for TB31F, combined with its retained nanomolar binding affinity and potent activity to inhibit parasite transmission, make this molecule an attractive biologic for malaria interventions.
Discussion
Pfs48/45 is a prominent target for the development of biomedical interventions that can interrupt the transmission of Pf and contribute to the decrease of malaria incidence. Here, we report the three-dimensional structure of the Pfs48/45 6C domain and delineate the epitope targeted by one of the most potent transmission-blocking mAbs yet described, 85RF45.1. Pfs48/45 6C adopts an SRS fold that consists of two β-sheets formed by a mix of parallel and anti-parallel β-strands. This fold has been proposed to derive from an ephrin-like precursor during evolution and is predicted to be adopted by at least 14 proteins in Pf 33, 34 . Correspondingly, proteins of known structures that have the highest structural homology are parasitic proteins of this s48/ 45 family for which structures have been determined: Pf12 (Pf), Pf41 (Pf), and Sporosag (Toxoplasma gondii). It is thought that these glycosylphosphatidylinositol (GPI)-anchored parasitic proteins play an important role in cell adhesion and immune evasion, although no exact function has yet been assigned to Pf12 and Pf41 34 . Our structure also reveals that the electrostatic surface of Pfs48/45 6C is highly electronegative. Whether this property is associated with its function in male gamete fertility 13 and involved in ligand binding or scaffolding in a multi-protein complex 35 will be an important area of further studies. It will also be important to determine whether the potency of mAb 85RF45.1 is associated with disruption of the Pfs48/45 epitope I in protein-protein interactions.
To obtain the crystal structure of the 85RF45. 31 are indicated in parentheses their exact composition is an area of active investigation [36] [37] [38] , but it remains largely unclear how frequent N-linked glycosylation is on Pf surface proteins in the presence of NXS/T sequons 39 . Here, we found N-linked glycosylation to be critical for monodisperse Pfs48/45 6C expression. Accordingly, we observed in our Pfs48/ 45 6C crystal structures that a NAG residue at position 303 can bury >150 Å 2 of surface area between two loops and mediates H-bonds with Pfs48/45 residues. Interestingly, in homologous merozoite protein Pf41, the location of the NAG residue in our Pfs48/45 6C structure is occupied by a helix from an upstream Pf41 N-terminal domain, which stacks against a similar groove. It is thus possible that in full-length Pfs48/45 elements located Nterminal of the Pfs48/45 6C fragment help stabilize the structure in a similar fashion. This hypothesis would be in agreement with the observation that refolding capacity was superior for a construct comprising both the middle four-cysteine domain and the C-terminal six-cysteine domain (10C) 15 . The success of fusing the N terminus of Pf glutamate-rich protein (PfGLURP R0 fragment) to express Pfs48/45 6C (R0.6C) 30 might also emanate from such favorable inter-domain stabilizing effects, possibly at the site occupied by the NAG residue here. Thus, our three-dimensional structures of Pfs48/45 6C now provide an opportunity for protein engineering to further stabilize the antigen, enhance its expression, and develop TBV immunogens that will optimally present epitope I to preferentially elicit potent transmission-blocking antibodies. mAb 85RF45.1 is one of the most potent antibodies identified against any transmission-blocking target, with an IC 80 of approximately 1-3 μg/mL in standard membrane feeding assay (SMFA) experiments. We also now reveal that its epitope is largely conserved: mAb 85RF45.1 can accommodate all sequence polymorphisms previously reported and still bind with nanomolar affinity. However, whether this antibody can block field isolates containing these polymorphisms remains to be determined. mAb 85RF45.1 represents a unique tool to assess the efficacy of antibodies to reduce Pf transmission and malaria incidence in affected communities. For this purpose, optimizing the developability of this rat-originating mAb was an important objective. Here, we show how humanization of mAb 85RF45.1 into mAb TB31F retained the exact molecular mode of recognition of Pfs48/45, its high-affinity binding to the antigen, and its potent transmission-reducing activity in SMFA. In addition, humanized TB31F Fab shows improved thermostability characteristics with~10°C higher T m and T agg compared to its ratderived counterpart. Thus, our data provide a salient example of how humanization can present an opportunity to simultaneously improve surface and biophysical profiles of non-human-derived mAbs, and will contribute to ongoing efforts to improve multiobjective antibody optimization functions 40, 41 .
mAb TB31F now offers a unique opportunity to test the efficacy of a Pfs48/45-based transmission-blocking intervention in humans. The mAb has entered good manufacturing production and preclinical safety testing. Phase I trials are planned to assess safety and tolerability. Pending a positive outcome, this will be followed by efficacy testing with the goal of establishing the level of mAb required to block parasite transmission from human to mosquito, as determined by direct skin feeding (infection prevalence endpoint). Comparison of these data to those from the laboratory-based SMFA, which employs an infection intensity (as opposed to infection prevalence) endpoint and is routinely used to inform go/no-go criteria in pre-and early-clinical testing, will enable "back-validation" of the SMFA to better inform its use as an early development stage-gate for measuring the efficacy of candidate vaccines and antibodies. Such results will also provide a benchmark for performance of future vaccines and validate the epitope studied here as an important target.
Methods
Cloning of the 85RF45.1 antibody from hybridoma. Sequencing and cloning of the rat hybridoma immunoglobulin genes were performed by LakePharma, Inc., Belmont, CA. Sequencing included cDNA synthesis, PCR with rat heavy and light chain primers, subcloning of correct-sized bands into TOPO vectors, and DNA sequencing of individual amplified clones. Native 85RF45.1 and chimeric 85RF45.1 (fused to human IgG1 constant regions) antibodies were cloned into LakePharma's high expression mammalian vector system and transient production was performed in HEK293 cells (Thermo Fisher Scientific). Starting at 20 h, and throughout the transient transfection production, antibody titers were measured (Octet QKe, ForteBio). Cultures were harvested at day 5 and antibodies in the conditioned media were purified using MabSelect SuRe Protein A resin (GE Healthcare) for validation.
Humanization of mAb 85RF45.1. Humanized antibodies were designed by creating multiple hybrid sequences that fuse select parts of the parental antibody sequence with the human framework sequences. Humanness scores, representing how human-like the antibody variable region sequence is, were calculated according to Gao et al. 42 . Based on the method employed, heavy chain scores of 79 or above were considered human-like; for lambda light chains, a score of 84 or above was considered humanlike. Full-length antibody genes for all nine heavy/light chain pairs were constructed by cloning the synthesized variable region sequences into expression vectors that contained the human IgG1 or lambda constant region genes.
Expression and purification of Fabs and antigens. The VL and VH regions of mAb TB31F and mAb 85RF45.1 were cloned into the pHLsec expression vector 43 upstream of human Igλ and CH1 constant regions, respectively. Fabs were expressed in HEK293F cells (Thermo Fisher Scientific) and purified by affinity chromatography using a HiTrap LambdaSelect column (GE Healthcare), followed by ion exchange (MonoS; GE Healthcare) and gel filtration (Superdex 200 Increase 10/300 GL; GE Healthcare) chromatography. The NF54 [https://www.ncbi.nlm.nih.gov/protein/ AHA91190.1] Pfs48/45 6C gene was codon-optimized for expression in mammalian cells, was cloned in the pHLsec expression vector 43 , and was purified by affinity chromatography (HisTrapFF; GE Healthcare) followed by gel filtration chromatography (Superdex 200 Increase 10/300 GL; GE Healthcare). The R0.6C protein was produced as previously described 30 .
Complex formation of Pfs48/45 6C with 85RF45.1 and TB31F Fabs. To obtain high yields of antigen-antibody complexes, plasmids for the TB31F and 85RF45.1 Fab heavy and light chains were mixed with the Pfs48/45 6C plasmid in a ratio of 60:30:40 and transfected in HEK293S cells (GnT I −/− ) (ATCC CRL-3022). 85RF45.1 Fab-Pfs48/45 6C and TB31F Fab-Pfs48/45 6C complexes were purified by affinity chromatography (HisTrapFF; GE Healthcare), treated with Endo H, and purified by cation exchange chromatography (MonoS; GE Healthcare).
Crystallization and structure determination. Hanging or sitting drop crystallization trials were set up using commercial sparse-matrix screens (Rigaku TOP96 and Anatrace MCSG 1) and hits were subsequently refined. 85RF45.1 and TB31F Fabs were set up at 8 mg/mL, while 85RF45.1 Fab-Pfs48/45 6C and TB31F FabPfs48/45 6C complexes were set up at 5 and 6 mg/mL, respectively. Crystals of the Fabs were obtained in the following crystallization conditions. 85RF45. Data were collected at the Canadian Light Source 08ID-1 beamline. Data processing and scaling was performed using XDS 44 . Phaser 45 was used for molecular replacement using Fabs from our internal database as starting models. AutoBuild 46 was used to build an initial model of Pfs48/45 6C, followed by manual building in Coot 47 . Structure refinement was carried out with phenix.refine 48 . Illustrations were generated using UCSF Chimera 49 and The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. Software used in this project was curated by SBGrid 50 . Representative electron density for the structures is shown in Supplementary Figure 7 .
Sequence polymorphism analysis. Deposited sequences for the Pfs48/45 6C fragment were obtained from the NCBI, PlasmoDB, and Uniprot databases. Sequence alignment was performed using Clustal Omega 51 .
BLI-binding studies. Binding kinetics studies for the two Fabs (85RF45.1 and TB31F) interacting with Pfs48/45 6C were conducted using an Octet RED96 system (Pall ForteBio). For Fab-Pfs48/45 6C binding experiments, Pfs48/45 6C monomers were loaded onto Ni-NTA biosensors followed by transfer into Fabcontaining wells. After the association steps were conducted, biosensors were then dipped into 1× kinetics buffer (1× PBS, pH 7.4, 0.002% (v/v) Tween-20, 0.01% (w/ v) BSA) to measure dissociation. Kinetics analysis was performed using the ForteBio data analysis software. For experiments to screen humanized variants of mAb 85RF45.1, the binding study involved immobilization of the antibodies onto antihuman Fc (AHC) biosensors followed by dipping into the R0.6C antigen in solution. 291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321  322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386  387  388  389  390  391  392  393  394  395  396  397  398  399  400  401  402  403  404  405  406  407  408  409  410  411  412  413  414  415  416  417  418  419  420  421  422  423  424  425  426  427 Melting and aggregation temperatures. Melting and aggregation temperatures for 85RF45.1 and TB31F Fabs were measured on a UNit system (Unchained Labs). The T m was obtained by measuring the barycentric mean fluorescence, and the T agg was determined from static light scattering measurements at a 266 nm wavelength during a temperature ramp from 20 to 95°C with 1°C increments. The equilibration time was set to 60 s before each measurement. The concentration of both samples was 1.0 mg/mL. Measurements were made in 100 mM sodium acetate, pH 5.6; 100 mM HEPES, pH 7.2; and 100 mM Tris, pH 9.0; all containing 150 mM NaCl. Measurements were made in triplicates, averaged, and standard errors were calculated by the UNit analysis software.
SMFA. SMFA experiments were conducted as previously described 52 using Anopheles stephensi mosquitoes that were reared and maintained at Radboudumc, and transgenic Pf NF54 (NF54-HGL) gametocytes that express luciferase 53 . Briefly, 3-5-day-old mosquitoes were fed on a glass mini-feeder system containing 0.27 mL of cultured Pf gametocytes mixed with human serum and monoclonal antibody. For each feed, two mini-feeders containing gametocytes and human serum only were used as a negative control. On day 9 after infection, four pools of five mosquitoes were collected for each condition, stored overnight at −20°C, homogenized by bead beating, and luciferase activity was quantified by measuring relative light units (RLU) 52 . The percentage transmission reduction activity (TRA) was calculated as 100 × [1−(RLU test sample)/(RLU control group)]. The best estimate and 95% confidence intervals from two separate feeds were calculated using a negative binomial model as previously described 54 without zero inflation.
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